Wilson Disease Drugs Market Size

  • Report ID: 2863
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Wilson Disease Drugs Market Size

Wilson Disease Drugs Market size was over USD 652.08 million in 2024 and is anticipated to cross USD 1.12 billion by 2037, witnessing more than 4.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of wilson disease drugs is estimated at USD 697.71 million.

The growth of the market can be attributed to the increasing prevalence of Wilson’s disease across the globe, especially in isolated areas. Wilson’s disease is caused by the mutation of the ATP7B gene which is passed on by parents to the child. This disease was observed to occur in 30,000 to 40,0000 people across the globe.

The advent of various organizations and associations in recent years, such as the Wilson Disease Association, an organization that endorses research and clinical investigations for Wilson disease and spreads awareness regarding the latest happening on the symptoms and treatment of Wilson disease, are observed to hike the market growth over the forecast period. Furthermore, the rising introduction of patient assistance programs which provides considerable growth opportunities to the companies for the development of novel therapeutic drugs for the treatment of Wilson disease is also anticipated to significantly propel the growth of the global Wilson disease drugs market during the forecast period. 


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2863
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of wilson disease drugs is estimated at USD 697.71 million.

The wilson disease drugs market size was over USD 652.08 million in 2024 and is anticipated to cross USD 1.12 billion by 2037, witnessing more than 4.3% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of Wilson’s disease in the young population and increasing health spending across the globe will boost the market growth.

North America industry is poised to dominate majority revenue share of 30% by 2037, propelled by presence of leading market players in the region which manufacture and distribute Wilson disease drugs.

The major players in the market are Merck & Co., Inc., Bausch Health Companies Inc., Alexion Pharmaceuticals, Inc., Nobelpharma Co., Ltd., Kodmon Holdings, Inc., Teva Pharmaceutical Industries Ltd., Tsumura & Co., VHB Medi Sciences Limited, Pfizer Inc., Lupin Limited, Vivet Therapeutics, NAVINTA LLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample